1Yu R,Kim CS,Kawada T,et al.Involvement of leukotactin-1,a novel CC chemokine,in human atherosclerosis[J].Atherosclerosis,2004; 174(1):35-42.
2Forssmann U,Magert HJ,Adermann K,et al.WG.Hemofiltrate CC chemokines with unique biochemical properties:HCC-1/CCL14a and HCC-2/CCL15[J].Leukoc Biol,2001 ;70(3):357-66.
3Lee JK,Kim HS,Im SA,et al.Identification of NH (2) -terminal amino acid residues essential for the biological activity of leukotactin-1[J].Immunol Lett,2005 ;99 (1):63-8.
4Ridker PM,Buring JE,Rifai N.Soluble P2 selectin and the risk of future cardiovascular events[J].Circulation,2001; 103:491-5.
5Zlotnik A,Yoshie O.Chemokines:a new classification system and their role in immunity[J].Immunity,2000 ;12:121-7.
6Murphy PM,Baggiolini M,Charo IF,et al.International union of pharmacology.ⅩⅫ Nomenclature for chemokine receptors[J].Pharmacol Rev,2000 ;52:145-7.
7Bochaer BS,Klunk DA,Sterbinsky SA,et al.Interleukin-13 selectively induces vascular adhesion molecule-1 (VCAM-1) expression in human endothelial cells[J].J Immunol,2000; 164:799-803.
